Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Respiratory viral surveillance of healthcare personnel and patients at an adult long-term care facility.

O'Neil CA, Kim L, Prill MM, Talbot HK, Whitaker B, Sakthivel SK, Zhang Y, Zhang J, Tong S, Stone N, Garg S, Gerber SI, Babcock HM.

Infect Control Hosp Epidemiol. 2019 Nov;40(11):1309-1312. doi: 10.1017/ice.2019.207. Epub 2019 Sep 25.

PMID:
31551105
2.

Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.

Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK; QHD00013 Study Group.

Vaccine. 2019 Sep 16;37(39):5825-5834. doi: 10.1016/j.vaccine.2019.08.016. Epub 2019 Aug 17.

3.

Comparison of a frailty short interview to a validated frailty index in adults hospitalized for acute respiratory illness.

Petrie JG, Martin ET, Zhu Y, Wyatt DG, Kaniclides A, Ferdinands JM, Monto AS, Trabue C, Talbot HK.

Vaccine. 2019 Jun 27;37(29):3849-3855. doi: 10.1016/j.vaccine.2019.05.051. Epub 2019 May 18.

PMID:
31113675
4.

Effects of Influenza Vaccination in the United States During the 2017-2018 Influenza Season.

Rolfes MA, Flannery B, Chung JR, O'Halloran A, Garg S, Belongia EA, Gaglani M, Zimmerman RK, Jackson ML, Monto AS, Alden NB, Anderson E, Bennett NM, Billing L, Eckel S, Kirley PD, Lynfield R, Monroe ML, Spencer M, Spina N, Talbot HK, Thomas A, Torres SM, Yousey-Hindes K, Singleton JA, Patel M, Reed C, Fry AM; US Influenza Vaccine Effectiveness (Flu VE) Network, the Influenza Hospitalization Surveillance Network, and the Assessment Branch, Immunization Services Division, Centers for Disease Control and Prevention .

Clin Infect Dis. 2019 Nov 13;69(11):1845-1853. doi: 10.1093/cid/ciz075.

PMID:
30715278
5.

Streptococcus pneumoniae colonization after introduction of 13-valent pneumococcal conjugate vaccine for US adults 65 years of age and older, 2015-2016.

Milucky J, Carvalho MG, Rouphael N, Bennett NM, Talbot HK, Harrison LH, Farley MM, Walston J, Pimenta F, Lessa FC; Adult Pneumococcal Carriage Study Group.

Vaccine. 2019 Feb 14;37(8):1094-1100. doi: 10.1016/j.vaccine.2018.12.075. Epub 2019 Jan 23.

6.

Streptococcus mitis Expressing Pneumococcal Serotype 1 Capsule.

Lessa FC, Milucky J, Rouphael NG, Bennett NM, Talbot HK, Harrison LH, Farley MM, Walston J, Pimenta F, Gertz RE, Rajam G, Carvalho MDG, Beall B, Whitney CG.

Sci Rep. 2018 Dec 19;8(1):17959. doi: 10.1038/s41598-018-35921-3.

7.

Prevention of Influenza Hospitalization Among Adults in the United States, 2015-2016: Results From the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).

Ferdinands JM, Gaglani M, Martin ET, Middleton D, Monto AS, Murthy K, Silveira FP, Talbot HK, Zimmerman R, Alyanak E, Strickland C, Spencer S, Fry AM; HAIVEN Study Investigators .

J Infect Dis. 2019 Sep 13;220(8):1265-1275. doi: 10.1093/infdis/jiy723.

PMID:
30561689
8.

Gastrointestinal Events in High-Dose vs Standard-Dose Influenza Vaccine Recipients.

Talbot HK, Dunning AJ, Robertson CA, Landolfi VA, Greenberg DP, DiazGranados CA.

Open Forum Infect Dis. 2018 May 22;5(6):ofy115. doi: 10.1093/ofid/ofy115. eCollection 2018 Jun 1.

9.

High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.

Vardeny O, Udell JA, Joseph J, Farkouh ME, Hernandez AF, McGeer AJ, Talbot HK, Bhatt DL, Cannon CP, Goodman SG, Anand I, DeMets DL, Temte J, Wittes J, Nichol K, Yancy CW, Gaziano JM, Cooper LS, Kim K, Solomon SD.

Am Heart J. 2018 Aug;202:97-103. doi: 10.1016/j.ahj.2018.05.007. Epub 2018 May 23.

10.

Respiratory Syncytial Virus and Associations With Cardiovascular Disease in Adults.

Ivey KS, Edwards KM, Talbot HK.

J Am Coll Cardiol. 2018 Apr 10;71(14):1574-1583. doi: 10.1016/j.jacc.2018.02.013. Review.

11.

Underdiagnosis of Influenza Virus Infection in Hospitalized Older Adults.

Hartman L, Zhu Y, Edwards KM, Griffin MR, Talbot HK.

J Am Geriatr Soc. 2018 Mar;66(3):467-472. doi: 10.1111/jgs.15298. Epub 2018 Feb 13.

12.

Incorporating Markers of Disease Severity into Near Real-Time Influenza Surveillance.

Grijalva CG, O'Donnell M, Talbot HK.

Ann Am Thorac Soc. 2017 Dec;14(12):1766-1767. doi: 10.1513/AnnalsATS.201709-719ED. No abstract available.

PMID:
29192823
13.

Preventing Respiratory Viral Transmission in Long-Term Care: Knowledge, Attitudes, and Practices of Healthcare Personnel.

O'Neil CA, Kim L, Prill MM, Stone ND, Garg S, Talbot HK, Babcock HM.

Infect Control Hosp Epidemiol. 2017 Dec;38(12):1449-1456. doi: 10.1017/ice.2017.232. Epub 2017 Nov 27.

PMID:
29173225
14.

2015-2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States.

Poehling KA, Caspard H, Peters TR, Belongia EA, Congeni B, Gaglani M, Griffin MR, Irving SA, Kavathekar PK, McLean HQ, Naleway AL, Ryan K, Talbot HK, Ambrose CS.

Clin Infect Dis. 2018 Feb 10;66(5):665-672. doi: 10.1093/cid/cix869.

15.

Influenza in Older Adults.

Talbot HK.

Infect Dis Clin North Am. 2017 Dec;31(4):757-766. doi: 10.1016/j.idc.2017.07.005. Epub 2017 Sep 12. Review.

PMID:
28911829
16.

Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines.

Kim L, Rha B, Abramson JS, Anderson LJ, Byington CL, Chen GL, DeVincenzo J, Edwards KM, Englund JA, Falsey AR, Griffin MR, Karron RA, Martin KG, Meissner HC, Munoz FM, Pavia AT, Piedra PA, Schaffner W, Simões EAF, Singleton R, Talbot HK, Walsh EE, Zucker JR, Gerber SI.

Clin Infect Dis. 2017 Sep 15;65(6):1020-1025. doi: 10.1093/cid/cix432.

17.

Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.

Greenberg DP, Robertson CA, Talbot HK, Decker MD.

Hum Vaccin Immunother. 2017 Sep 2;13(9):2058-2064. doi: 10.1080/21645515.2017.1344375.

18.

Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses.

Falloon J, Talbot HK, Curtis C, Ervin J, Krieger D, Dubovsky F, Takas T, Yu J, Yu L, Lambert SL, Villafana T, Esser MT.

Clin Vaccine Immunol. 2017 Sep 5;24(9). pii: e00157-17. doi: 10.1128/CVI.00157-17. Print 2017 Sep.

19.

Sensitive Diagnostics Confirm That Influenza C is an Uncommon Cause of Medically Attended Respiratory Illness in Adults.

Nesmith N, Williams JV, Johnson M, Zhu Y, Griffin M, Talbot HK.

Clin Infect Dis. 2017 Sep 15;65(6):1037-1039. doi: 10.1093/cid/cix471.

20.

Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014-2015 season.

McLean HQ, Caspard H, Griffin MR, Poehling KA, Gaglani M, Belongia EA, Talbot HK, Peters TR, Murthy K, Ambrose CS.

Vaccine. 2017 May 9;35(20):2685-2693. doi: 10.1016/j.vaccine.2017.03.085. Epub 2017 Apr 10.

21.

Risk Factors for Outpatient Use of Antibiotics in Children with Acute Respiratory Illnesses.

Zhao SR, Griffin MR, Patterson BL, Mace RL, Wyatt D, Zhu Y, Talbot HK.

South Med J. 2017 Mar;110(3):172-180. doi: 10.14423/SMJ.0000000000000622.

22.

Paramyxovirus Outbreak in a Long-Term Care Facility: The Challenges of Implementing Infection Control Practices in a Congregate Setting.

Spires SS, Talbot HK, Pope CA, Talbot TR.

Infect Control Hosp Epidemiol. 2017 Apr;38(4):399-404. doi: 10.1017/ice.2016.316. Epub 2017 Jan 9.

PMID:
28065183
23.

Greater activation of peripheral T follicular helper cells following high dose influenza vaccine in older adults forecasts seroconversion.

Pilkinton MA, Nicholas KJ, Warren CM, Smith RM, Yoder SM, Talbot HK, Kalams SA.

Vaccine. 2017 Jan 5;35(2):329-336. doi: 10.1016/j.vaccine.2016.11.059. Epub 2016 Dec 3.

24.

Reply to Sullivan et al.

Chen Q, Nian H, Zhu Y, Talbot HK.

Vaccine. 2016 Sep 7;34(39):4647-8. doi: 10.1016/j.vaccine.2016.08.008. No abstract available.

PMID:
27578297
25.

Reply to Skowronski et al.

DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP.

Clin Infect Dis. 2016 Nov 1;63(9):1267. Epub 2016 Aug 9. No abstract available.

PMID:
27506683
26.

High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses.

Kim JH, Talbot HK, Mishina M, Zhu Y, Chen J, Cao W, Reber AJ, Griffin MR, Shay DK, Spencer SM, Sambhara S.

Vaccine. 2016 Aug 31;34(38):4594-4601. doi: 10.1016/j.vaccine.2016.07.018. Epub 2016 Jul 26.

27.

Too many covariates and too few cases? - a comparative study.

Chen Q, Nian H, Zhu Y, Talbot HK, Griffin MR, Harrell FE Jr.

Stat Med. 2016 Nov 10;35(25):4546-4558. doi: 10.1002/sim.7021. Epub 2016 Jun 30.

28.

Age, serum 25-hydroxyvitamin D and vitamin D receptor (VDR) expression and function in peripheral blood mononuclear cells.

Coleman LA, Mishina M, Thompson M, Spencer SM, Reber AJ, Davis WG, Cheng PY, Belongia EA, Talbot HK, Sundaram ME, Griffin MR, Shay DK, Sambhara S.

Oncotarget. 2016 Jun 14;7(24):35512-35521. doi: 10.18632/oncotarget.9398.

29.

Detection of influenza by real time RT-PCR is not affected by delays in respiratory specimen processing.

Dare R, Zhu Y, Williams JV, Griffin M, Talbot HK.

J Med Virol. 2016 Nov;88(11):1891-5. doi: 10.1002/jmv.24549. Epub 2016 Apr 26.

30.

Vertical Transmission of Histoplasmosis Associated With Anti-Tumor Necrosis Factor Therapy.

Carlucci JG, Halasa N, Creech CB, Dulek DE, Gómez-Duarte OG, Nelson GE, Talbot HK, Scalise ML, Scott PL, Mahadevan U, Beaulieu DB.

J Pediatric Infect Dis Soc. 2016 Jun;5(2):e9-e12. doi: 10.1093/jpids/piw001. Epub 2016 Mar 24.

31.

Evaluating the case-positive, control test-negative study design for influenza vaccine effectiveness for the frailty bias.

Talbot HK, Nian H, Chen Q, Zhu Y, Edwards KM, Griffin MR.

Vaccine. 2016 Apr 4;34(15):1806-9. doi: 10.1016/j.vaccine.2016.02.037. Epub 2016 Feb 28.

32.

Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults.

DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP.

Clin Infect Dis. 2016 May 1;62(9):1092-1099. doi: 10.1093/cid/ciw085. Epub 2016 Feb 21.

33.

Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial.

Dunning AJ, DiazGranados CA, Voloshen T, Hu B, Landolfi VA, Talbot HK.

Clin Vaccine Immunol. 2016 Jan 13;23(3):228-35. doi: 10.1128/CVI.00604-15.

34.

Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine.

Chung JR, Flannery B, Thompson MG, Gaglani M, Jackson ML, Monto AS, Nowalk MP, Talbot HK, Treanor JJ, Belongia EA, Murthy K, Jackson LA, Petrie JG, Zimmerman RK, Griffin MR, McLean HQ, Fry AM.

Pediatrics. 2016 Feb;137(2):e20153279. doi: 10.1542/peds.2015-3279. Epub 2016 Jan 5.

35.

Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States.

Caspard H, Gaglani M, Clipper L, Belongia EA, McLean HQ, Griffin MR, Talbot HK, Poehling KA, Peters TR, Veney N, Ambrose CS.

Vaccine. 2016 Jan 2;34(1):77-82. doi: 10.1016/j.vaccine.2015.11.010. Epub 2015 Nov 14.

PMID:
26589519
36.

Preexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses.

Reber AJ, Kim JH, Biber R, Talbot HK, Coleman LA, Chirkova T, Gross FL, Steward-Clark E, Cao W, Jefferson S, Veguilla V, Gillis E, Meece J, Bai Y, Tatum H, Hancock K, Stevens J, Spencer S, Chen J, Gargiullo P, Braun E, Griffin MR, Sundaram M, Belongia EA, Shay DK, Katz JM, Sambhara S.

Open Forum Infect Dis. 2015 Apr 15;2(2):ofv052. doi: 10.1093/ofid/ofv052. eCollection 2015 Apr.

37.

Hospitalizations and outpatient visits for rhinovirus-associated acute respiratory illness in adults.

Miller EK, Linder J, Kraft D, Johnson M, Lu P, Saville BR, Williams JV, Griffin MR, Talbot HK.

J Allergy Clin Immunol. 2016 Mar;137(3):734-43.e1. doi: 10.1016/j.jaci.2015.06.017. Epub 2015 Aug 6.

38.

Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines.

DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, Greenberg DP.

Vaccine. 2015 Sep 11;33(38):4988-93. doi: 10.1016/j.vaccine.2015.07.006. Epub 2015 Jul 26.

39.

Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty.

DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP.

Vaccine. 2015 Aug 26;33(36):4565-71. doi: 10.1016/j.vaccine.2015.07.003. Epub 2015 Jul 14.

40.

Factors associated with maintenance of antibody responses to influenza vaccine in older, community-dwelling adults.

Talbot HK, Coleman LA, Zhu Y, Spencer S, Thompson M, Cheng PY, Sundaram ME, Belongia EA, Griffin MR.

BMC Infect Dis. 2015 Apr 23;15:195. doi: 10.1186/s12879-015-0926-8.

41.

Antiviral treatment among older adults hospitalized with influenza, 2006-2012.

Lindegren ML, Griffin MR, Williams JV, Edwards KM, Zhu Y, Mitchel E, Fry AM, Schaffner W, Talbot HK.

PLoS One. 2015 Mar 25;10(3):e0121952. doi: 10.1371/journal.pone.0121952. eCollection 2015.

42.

Update on vaccination guidelines for older adults.

Pilkinton MA, Talbot HK.

J Am Geriatr Soc. 2015 Mar;63(3):584-8. doi: 10.1111/jgs.13375. Epub 2015 Mar 6.

PMID:
25753174
43.

Clinical effectiveness of split-virion versus subunit trivalent influenza vaccines in older adults.

Talbot HK, Nian H, Zhu Y, Chen Q, Williams JV, Griffin MR.

Clin Infect Dis. 2015 Apr 15;60(8):1170-5. doi: 10.1093/cid/civ019. Epub 2015 Feb 18.

44.

Influenza-related hospitalization and ED visits in children less than 5 years: 2000-2011.

Jules A, Grijalva CG, Zhu Y, Talbot HK, Williams JV, Poehling KA, Chaves SS, Edwards KM, Schaffner W, Shay DK, Griffin MR.

Pediatrics. 2015 Jan;135(1):e66-74. doi: 10.1542/peds.2014-1168. Epub 2014 Dec 8.

45.

Influenza vaccine prevents medically attended influenza-associated acute respiratory illness in adults aged ≥50 years.

Chen Q, Griffin MR, Nian H, Zhu Y, Williams JV, Edwards KM, Talbot HK.

J Infect Dis. 2015 Apr 1;211(7):1045-50. doi: 10.1093/infdis/jiu578. Epub 2014 Oct 21.

46.

Provider knowledge of trivalent inactivated and high-dose influenza vaccines.

Tewell C, Wright PW, Talbot HK.

Vaccine. 2014 Oct 21;32(46):6025-8. doi: 10.1016/j.vaccine.2014.08.081. Epub 2014 Sep 22.

47.

Efficacy of high-dose versus standard-dose influenza vaccine in older adults.

DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, Martin E, Gurunathan S, Nathan R, Greenberg DP, Tornieporth NG, Decker MD, Talbot HK.

N Engl J Med. 2014 Aug 14;371(7):635-45. doi: 10.1056/NEJMoa1315727.

48.

Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults.

Widmer K, Griffin MR, Zhu Y, Williams JV, Talbot HK.

Influenza Other Respir Viruses. 2014 May;8(3):347-52. doi: 10.1111/irv.12234. Epub 2014 Feb 7.

49.

Respiratory virus shedding in a cohort of on-duty healthcare workers undergoing prospective surveillance.

Esbenshade JC, Edwards KM, Esbenshade AJ, Rodriguez VE, Talbot HK, Joseph MF, Nwosu SK, Chappell JD, Gern JE, Williams JV, Talbot TR.

Infect Control Hosp Epidemiol. 2013 Apr;34(4):373-8. doi: 10.1086/669857. Epub 2013 Feb 8.

50.

Vitamin D is not associated with serologic response to influenza vaccine in adults over 50 years old.

Sundaram ME, Talbot HK, Zhu Y, Griffin MR, Spencer S, Shay DK, Coleman LA.

Vaccine. 2013 Apr 12;31(16):2057-61. doi: 10.1016/j.vaccine.2013.02.028. Epub 2013 Feb 28.

PMID:
23453766

Supplemental Content

Loading ...
Support Center